Close

Search

Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
SPECIAL ANNOUNCEMENT
2016 Photonics Buyers' Guide Clearance! – Use Coupon Code FC16 to save 60%!
share
Email Facebook Twitter Google+ LinkedIn Comments

Norwood Abbey Gets Nod for Laser Drug Device

Photonics.com
Jan 2003
MELBOURNE, Australia, Jan. 15 -- The US Food and Drug Administration (FDA) has granted 510(k) marketing approval for Norwood Abbey Ltd.'s laser-assisted drug delivery (LAD) device for "ablation of the outer layer of the skin prior to the application of OTC topical 4 percent lidocaine cream, for local dermal anesthesia."

The LAD, compromising a laser device and single-use disposable tips, is designed to painlessly and temporarily alter the stratum corneum, or outer layer of skin, for more effective delivery of topically applied drugs.

Norwood's North American marketing partner for the LAD, Ferndale Laboratories Inc., will package Norwood disposable LAD tips with its over-the-counter topical anaesthetic, Ela-Max. Mark McLoughlin was appointed a vice-president for the laser project in North America.

The primary market for the product is expected to be patients undergoing various procedures requiring needle-sticks, including injections, intravenous insertions and blood donations. The company is targeting clinicians in dermatology/plastic surgery, oncology pediatrics, and blood donation facilities.; Norwood said it expects to sell or place 10,000 devices by the end of 2005.

For more information, visit: www.norwoodabbey.com



Comments
Terms & Conditions Privacy Policy About Us Contact Us
back to top

Facebook Twitter Instagram LinkedIn YouTube RSS
©2016 Photonics Media
x We deliver – right to your inbox. Subscribe FREE to our newsletters.